Analysis Reveals 'Female Libido' Pill May Not Be Worth It

This article originally appeared here.
Share this content:
Analysis Reveals 'Female Libido' Pill May Not Be Worth It
Analysis Reveals 'Female Libido' Pill May Not Be Worth It

MONDAY, Feb. 29, 2016 (HealthDay News) -- Flibanserin (Addyi), the "female libido" pill, appears to cause many serious side effects while failing to increase the desire for sexual activity, according to a review published online Feb. 29 in JAMA Internal Medicine.

Ellen Laan, Ph.D., professor of sexology and psychosomatic gynecology at the University of Amsterdam, and colleagues reviewed eight clinical trials conducted with flibanserin, including five published and three unpublished studies involving 5,914 women.

The combined evidence showed that flibanserin provides marginal benefit for women who are suffering hypoactive sexual desire disorder. For example, women taking the medication scored just 0.3 points higher on a 5-point sexual desire scale and experienced a minimal increase in satisfying sexual events each month, the review authors found. But flibanserin also quadruples the risk of dizziness and sleepiness, more than doubles the chances of nausea, and increases the risk of fatigue by more than half, according to the analysis.

"We found women had, on average, 2.5 satisfying sexual events per month before entering the study, and flibanserin added one-half additional satisfying sexual events per month," Laan told HealthDay.

Abstract
Full Text
Editorial

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

NIH Panel Will No Longer Review Gene Therapy Experiments

NIH Panel Will No Longer Review Gene Therapy ...

FDA will now assess gene therapy experiments and products as it does with other treatments, drugs

is free, fast, and customized just for you!




Already a member?

Sign In Now »